Clinical Studies

Home / Clinical Studies

Pilot Studies

Keeogo™ has been used by multiple volunteers in controlled and uncontrolled studies with the multiple sclerosis, knee & hip osteoarthritis, Parkinson’s disease and peripheral artery disease patient populations and the following collaborators:

Investigators

  • Laurent Bouyer, PhD, Caroline Rahn, PT, François Routhier, PEng, PhD, Bradford McFadyen, PhD, Center for Interdisciplinary Research in Rehabilitation and Social Integration, IRDPQ, Unversité Laval.
  • Emmanuelle Pourcher MD,Msc,FRCP(C) Neurologist-Movement Disorders Specialist , Neuropharmacologist and Neuropsychiatrist.Clinique Sainte Anne Mémoire et Mouvement /,CHU de Québec / and / , Quebec Mental Health University Institute Research Center, Philippe Corbeil, PhD Kinesiology, Faculty of Medicine, Kinesiology Department, Université Laval, Centre de recherche du CHU de Québec.
  • Dr. Paul Poirier MD PhD, FACC, FAHA, FRCPC, Institut Universitaire de Cardiologie et de Pneumologie de Québec.

Multi-Center Pivotal Clinical Trial

B-TEMIA Inc. has initiated a multi-center pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of Keeogo™, for patients living with reduced mobility due to medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick’s, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.
“This is the first international clinical trial involving the Dermoskeleton™ technology that aims at demonstrating the efficacy and safety of Keeogo™ during everyday community and home mobility use, something that has not been possible in the past with other exoskeleton technologies that were developed principally for use in a clinical rehabilitation setting”, stated Dr. Chris A. McGibbon.

As part of the trial, B-TEMIA has partnered with three of the most reputable rehabilitation institutions in North America: the Rehabilitation Institute of Chicago, the Spaulding Rehabilitation Hospital Boston, and the Toronto Rehabilitation Institute–UHN.

To learn more about how you or your patients may be involved in this clinical trial, contact info@b-temia.com.

Nous joindre

Nous vous reviendrons dès que possible.